IL17C and COVID-19: Among the 12 patients who did not generate detectable antibodies, we observed a significantly elevated level of IL17C and a protein in the PPAR signaling pathway, namely, FABP6, compared to patients with COVID-19 with detectable antibodies (Figure 4b, Table S6).